Updated: New Apple Tree biotech emerges with antibodies that might pair with Amgen, Mirati's KRAS drugs
Apple Tree Partners is out Monday with a new biotech from the labs of NYU Langone Health that aims to tackle drug resistance in cancer.
Aethon Therapeutics will get $25 million from the VC firm, and another $5 million from New York University and other investors, the New York-based biotech said Monday.
The fledgling startup is working off a so-called HapImmune immunotherapy platform from the labs of Shohei Koide and Benjamin Neel at NYU’s Perlmutter Cancer Center. The two researchers began pondering the idea about three and a half years ago, Neel told Endpoints News, and they came to Apple Tree’s head of oncology Raj Chopra about a year ago to form the company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.